PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-21.98%
Both yoy net incomes decline, with AGEN at -15.19%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
22.78%
D&A growth well above AGEN's 1.01%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
128.24%
SBC growth while AGEN is negative at -3.91%. John Neff would see competitor possibly controlling share issuance more tightly.
-92.68%
Negative yoy working capital usage while AGEN is 372.93%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
314.60%
A yoy AP increase while AGEN is negative at -87.78%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
26.98%
Some yoy usage while AGEN is negative at -89.57%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-101.99%
Negative yoy while AGEN is 84.53%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-120.47%
Negative yoy CFO while AGEN is 25.92%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
72.96%
CapEx growth well above AGEN's 14.81%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.96%
We have mild expansions while AGEN is negative at -285.31%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
86.96%
We repay more while AGEN is negative at -52.17%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-90.54%
Both yoy lines negative, with AGEN at -1.44%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.